Stay updated on Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 was added and Revision: v3.4.1 was removed, both as site-wide versioning updates that do not affect the trial details or data on this page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check20 days agoChange DetectedAdded a government funding–related notice about possible delays in updating information. Updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedThe page now includes a 'Show glossary' option, adds 'No FEAR Act Data' and 'Revision: v3.4.0' in the footer, and updates the label to 'Last Update Submitted that Met QC Criteria'.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision v3.3.4 added and revision v3.3.3 removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedA new study location in Illinois was added and the footer revision updated to v3.3.3; the HHS Vulnerability Disclosure entry was removed.SummaryDifference0.2%

- Check92 days agoChange DetectedPublication notes now state that PubMed publications are auto-filled, and the old PubMed wording was removed; the page revision has been updated to v3.3.2, replacing the previous v3.2.0.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Capecitabine in TNBC/HR+ Breast Cancer Clinical Trial page.